Home-Based Administration Of Fecal Microbiota, Live-Jslm Effective For Patients With CDI Recurrence, Study Finds

Infectious Disease Advisor (6/11, Kuhns) reports a study found that “fecal microbiota, live-jslm (REBYOTA® [RBL]) is effective for preventing recurrent Clostridioides difficile infection (CDI) among high-risk patients in both clinic and at-home settings.” Researchers observed that at “8 weeks following RBL administration, the overall treatment success rate was 83.0%. However, 14.8% of patients experienced CDI recurrence, and 2.2% had missing outcome data. Overall, home-based administration of RBL was associated with significantly higher treatment success rates than clinic-based administration (87.3% and 62.5%, respectively).” Subgroup analyses indicated “no significant differences in treatment success rates in patients stratified by age, antibiotic washout period, number of prior CDI episodes, or prior bezlotoxumab use.” The study was published in Infectious Diseases and Therapy.